Cancer Research Technology Limited

Kate Mary Smith

Allan Michael Jordan

James R Hitchin

Niall M Hamilton

Colin P Hutton

Ian D Waddell

Alison E McGonagle

Bohdan Waszkowycz

Bodhan Waszkowycz

Alison E Mcgonagle

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R, R, R, R, W, X, X, X, X, X, X, X, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

PARG inhibitory compounds

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity: wherein R, R, R, R, R, W, X, X, X, X, X, X, X, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated. 

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R, R, R, R, R, W, X, X, X, X, X, X, X, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated. 

2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG

Growing community of inventors

Manchester, United Kingdom

Kate Mary Smith